One-year efficacy and safety of Web-based follow-up using cellular phone in type 1 diabetic patients under insulin pump therapy: the PumpNet study - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.1016/j.diabet.2007.01.002. Epub 2007 Mar 28.
Affiliations
- PMID: 17395516
- DOI: 10.1016/j.diabet.2007.01.002
Randomized Controlled Trial
One-year efficacy and safety of Web-based follow-up using cellular phone in type 1 diabetic patients under insulin pump therapy: the PumpNet study
P-Y Benhamou et al. Diabetes Metab. 2007 Jun.
Abstract
Aim: Conventional follow-up of type 1 diabetic patients treated with continuous subcutaneous insulin infusion (CSII) was compared with intensive coaching using the Web and the cellular phone network for retrospective data transmission and short message service (SMS).
Methods: Thirty poorly controlled patients (HbA1c 7.5-10%) were enrolled in a bicenter, open-label, randomized, 12-month, two-period, crossover study. After a 1-month run-in period, 15 patients were randomly assigned to receive weekly medical support through SMS based upon weekly review of glucose values, while 15 patients continued to download self-monitored blood glucose (SMBG) values on a weekly basis without receiving SMS. After 6 months, patients crossed over to the alternate sequence for 6 additional months. Visits at the clinic were maintained every 3 months.
Results: Patients with long-standing inadequately controlled diabetes (24 +/- 13 years) were included. A non-significant trend to reduction in HbA(1c) (-0.25+/-0.94%, P<0.10) and mean glucose values (-9.2+/-25 mg/dl, P=0.06) during the 6-month SMS sequence was observed as compared with the no-SMS period. No safety issue (hypoglycemia, glucose variability) was reported. Adherence to SMBG was not affected by the trial. Quality of life analysis suggests a significant improvement in DQOL global score, as well as the DQOL satisfaction with life subscale, during the SMS sequence.
Conclusions: Long-term telemedical follow-up of insulin pump-treated patients using a cellular phone-, SMS- and Web-based platform is feasible, safe, does not alter quality of life and associated with a trend toward improved metabolic control.
Similar articles
- Continuous glucose monitoring reduces both hypoglycaemia and HbA1c in hypoglycaemia-prone type 1 diabetic patients treated with a portable pump.
Radermecker RP, Saint Remy A, Scheen AJ, Bringer J, Renard E. Radermecker RP, et al. Diabetes Metab. 2010 Nov;36(5):409-13. doi: 10.1016/j.diabet.2010.08.001. Epub 2010 Sep 22. Diabetes Metab. 2010. PMID: 20864372 - Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials.
Pala L, Dicembrini I, Mannucci E. Pala L, et al. Acta Diabetol. 2019 Sep;56(9):973-980. doi: 10.1007/s00592-019-01326-5. Epub 2019 Apr 3. Acta Diabetol. 2019. PMID: 30945047 - Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial.
Hoogma RP, Hammond PJ, Gomis R, Kerr D, Bruttomesso D, Bouter KP, Wiefels KJ, de la Calle H, Schweitzer DH, Pfohl M, Torlone E, Krinelke LG, Bolli GB; 5-Nations Study Group. Hoogma RP, et al. Diabet Med. 2006 Feb;23(2):141-7. doi: 10.1111/j.1464-5491.2005.01738.x. Diabet Med. 2006. PMID: 16433711 Clinical Trial. - Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis.
Yeh HC, Brown TT, Maruthur N, Ranasinghe P, Berger Z, Suh YD, Wilson LM, Haberl EB, Brick J, Bass EB, Golden SH. Yeh HC, et al. Ann Intern Med. 2012 Sep 4;157(5):336-47. doi: 10.7326/0003-4819-157-5-201209040-00508. Ann Intern Med. 2012. PMID: 22777524 Review. - Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation.
Riemsma R, Corro Ramos I, Birnie R, Büyükkaramikli N, Armstrong N, Ryder S, Duffy S, Worthy G, Al M, Severens J, Kleijnen J. Riemsma R, et al. Health Technol Assess. 2016 Feb;20(17):v-xxxi, 1-251. doi: 10.3310/hta20170. Health Technol Assess. 2016. PMID: 26933827 Free PMC article. Review.
Cited by
- Computerized Automated Reminder Diabetes System (CARDS): e-mail and SMS cell phone text messaging reminders to support diabetes management.
Hanauer DA, Wentzell K, Laffel N, Laffel LM. Hanauer DA, et al. Diabetes Technol Ther. 2009 Feb;11(2):99-106. doi: 10.1089/dia.2008.0022. Diabetes Technol Ther. 2009. PMID: 19848576 Free PMC article. - Effect of Training through Short Message Service on Compliance and Mean Blood Pressure of Hypertensive Patients.
Movahedi M, Khadivi R, Rouzbahani R, Tavakoli-Fard N. Movahedi M, et al. Int J Prev Med. 2019 Nov 28;10:200. doi: 10.4103/ijpvm.IJPVM_507_17. eCollection 2019. Int J Prev Med. 2019. PMID: 31879549 Free PMC article. - The Impact of Information Technology on Patient Engagement and Health Behavior Change: A Systematic Review of the Literature.
Sawesi S, Rashrash M, Phalakornkule K, Carpenter JS, Jones JF. Sawesi S, et al. JMIR Med Inform. 2016 Jan 21;4(1):e1. doi: 10.2196/medinform.4514. JMIR Med Inform. 2016. PMID: 26795082 Free PMC article. - Text messaging as a tool for behavior change in disease prevention and management.
Cole-Lewis H, Kershaw T. Cole-Lewis H, et al. Epidemiol Rev. 2010;32(1):56-69. doi: 10.1093/epirev/mxq004. Epub 2010 Mar 30. Epidemiol Rev. 2010. PMID: 20354039 Free PMC article. Review. - Diabetes self-management smartphone application for adults with type 1 diabetes: randomized controlled trial.
Kirwan M, Vandelanotte C, Fenning A, Duncan MJ. Kirwan M, et al. J Med Internet Res. 2013 Nov 13;15(11):e235. doi: 10.2196/jmir.2588. J Med Internet Res. 2013. PMID: 24225149 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous